GSK · NYSE · STOCK
GSK plc
$50.91
52W $37.80 – $61.70
64/100
$101.98B
15.8
0.30
Is GSK Bullish or Bearish?
Mixed.
Innellis AI committee rates GSK plc (GSK) Insufficient Data with a composite score of 64/100
, based on 3 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
No threshold can be published for GSK. The committee has not produced a scored recommendation, so there is no line for it to cross. Innellis does not infer one.
Executive Summary
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull & Bear Case
Bull Case
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
- News sentiment is positive (+0.27 across 20 articles, 14d) — News
Bear Case
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
64/100
Agreement
67%
Analysts
3
Conviction
Low Data
Sector Rank
Top 22%
of 192 Healthcare peers
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 20 articles, 14d)
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
39.2
Neutral
MACD Histogram
-0.026
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$48.58
Resistance
$59.56
Bollinger %B
0.27
Inside Bands
Price vs Moving Averages
EMA 9
$51.87
Below
EMA 21
$51.89
Below
EMA 50
$51.99
Below
EMA 200
$50.55
Above
Fundamental Analysis
Valuation
85
Profitability
92
Financial Health
37
Cash Flow
70
Valuation
P/E Ratio
15.8×
P/B Ratio
4.31×
PEG Ratio
0.37
Dividend Yield
3.53%
52W High
$61.70
52W Low
$37.80
Quality & Growth
ROE
3496.4%
ROA
936.9%
Gross Margin
7328.6%
Operating Margin
2411.5%
Revenue Growth YoY
—
Debt / Equity
1.03
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of 15.8 (inexpensive relative to a 15-40x range); Price-to-book of 4.3x; PEG ratio of 0.4 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 35.0%; Return on assets of 9.4%; Net margin of 14.5%; Gross margin of 73.3%; Current ratio of 0.82 (tight short-term liquidity); Debt-to-equity of 1.03; Free cash flow per share is positive (2.87); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full GSK Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →